142 related articles for article (PubMed ID: 24409199)
1. The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.
Milo R
Ther Adv Neurol Disord; 2014 Jan; 7(1):7-21. PubMed ID: 24409199
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on daclizumab: its potential in the treatment of multiple sclerosis.
Milo R; Stüve O
Degener Neurol Neuromuscul Dis; 2016; 6():95-109. PubMed ID: 30050372
[TBL] [Abstract][Full Text] [Related]
3. Daclizumab therapy for multiple sclerosis.
Bielekova B
Neurotherapeutics; 2013 Jan; 10(1):55-67. PubMed ID: 23055048
[TBL] [Abstract][Full Text] [Related]
4. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis.
Cohan S
Biologics; 2016; 10():119-38. PubMed ID: 27672308
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.
Perry JS; Han S; Xu Q; Herman ML; Kennedy LB; Csako G; Bielekova B
Sci Transl Med; 2012 Aug; 4(145):145ra106. PubMed ID: 22855463
[TBL] [Abstract][Full Text] [Related]
7. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis.
Jiang W; Chai NR; Maric D; Bielekova B
J Immunol; 2011 Jul; 187(2):781-90. PubMed ID: 21666061
[TBL] [Abstract][Full Text] [Related]
8. Daclizumab (anti-CD25) in multiple sclerosis.
Pfender N; Martin R
Exp Neurol; 2014 Dec; 262 Pt A():44-51. PubMed ID: 24768797
[TBL] [Abstract][Full Text] [Related]
9. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
[TBL] [Abstract][Full Text] [Related]
10. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Giovannoni G; Gold R; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; McNeill M; Amaravadi L; Sweetser M; Elkins J; O'Neill G;
Lancet Neurol; 2014 May; 13(5):472-81. PubMed ID: 24656609
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Oh J; Saidha S; Cortese I; Ohayon J; Bielekova B; Calabresi PA; Newsome SD
Neurology; 2014 Mar; 82(11):984-8. PubMed ID: 24532277
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova E; Stefoski D; Sprenger T; Montalban X; Cohan S; Umans K; Greenberg SJ; Ozen G; Elkins J
BMC Neurol; 2016 Jul; 16():117. PubMed ID: 27461166
[TBL] [Abstract][Full Text] [Related]
13. CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
Elkins J; Sheridan J; Amaravadi L; Riester K; Selmaj K; Bielekova B; Parr E; Giovannoni G
Neurol Neuroimmunol Neuroinflamm; 2015 Apr; 2(2):e65. PubMed ID: 25635261
[TBL] [Abstract][Full Text] [Related]
14. Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies.
Singer BA
Semin Neurol; 2016 Apr; 36(2):140-7. PubMed ID: 27116720
[TBL] [Abstract][Full Text] [Related]
15. New management algorithms in multiple sclerosis.
Sorensen PS
Curr Opin Neurol; 2014 Jun; 27(3):246-59. PubMed ID: 24759080
[TBL] [Abstract][Full Text] [Related]
16. Novel Agents for Relapsing Forms of Multiple Sclerosis.
Straus Farber R; Harel A; Lublin F
Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
[TBL] [Abstract][Full Text] [Related]
17. Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.
Lin YC; Winokur P; Blake A; Wu T; Romm E; Bielekova B
Ann Clin Transl Neurol; 2015 May; 2(5):445-55. PubMed ID: 26000318
[TBL] [Abstract][Full Text] [Related]
18. A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.
D'Amico E; Messina S; Caserta C; Patti F
Expert Opin Drug Saf; 2015 Jul; 14(7):1157-68. PubMed ID: 25826609
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
